Pseudomonas aeruginosa-driven Humoral Immune Activation in Lung Transplantation: A Treatable Trait to Avert Chronic Lung Allograft Dysfunction?

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Transplantation

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0000000000005566PMID 41211870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres

  2025cited by this paper
• Humoral immunity to lung antigens early post-transplant confers risk for chronic lung allograft dysfunction.

  2025cited by this paper
• Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial

  2025cited by this paper
• Pseudomonas aeruginosa infection induces intragraft lymphocytotoxicity that triggers lung transplant antibody-mediated rejection.

  2025cited by this paper
• Clinical predictors for restrictive allograft syndrome: a nested case-control study.

  2025cited by this paper
• Protective effects of neutrophil serine protease inhibition against ischemia–reperfusion injury in lung or heart transplantation

  2025cited by this paper
• Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety

  2024cited by this paper
• Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

  2024cited by this paper
• Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction

  2024cited by this paper
• Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms

  2024cited by this paper
• Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival

  2024cited by this paper
• Management of infectious disease syndromes in thoracic organ transplants and mechanical circulatory device recipients: a Delphi panel

  2024cited by this paper
• The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Patients with Chronic Rejection.

  2024cited by this paper
• Prognostic Value of Chest CT Findings at BOS Diagnosis in Lung Transplant Recipients

  2023cited by this paper
• Mechanism of resistance to phagocytosis and pulmonary persistence in mucoid Pseudomonas aeruginosa

  2023cited by this paper
• Neutrophil Dysfunction in the Pathogenesis of Cystic Fibrosis.

  2022cited by this paper
• IL-33 mediates Pseudomonas induced airway fibrogenesis and is associated with CLAD.

  2022cited by this paper
• Extracellular Vesicles Mediate Immune Responses to Tissue-Associated Self-Antigens: Role in Solid Organ Transplantations

  2022cited by this paper
• Evaluation of Selected Parameters of the Specific Immune Response against Pseudomonas aeruginosa Strains

  2021cited by this paper
• Cystic Fibrosis Lung Transplant Recipients Have Suppressed Airway Interferon Responses during Pseudomonas Infection

  2020cited by this paper
• Pseudomonas aeruginosa and acute rejection independently increase the risk of donor‐specific antibodies after lung transplantation

  2020cited by this paper
• Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis

  2020cited by this paper
• Tolerance and Persistence of Pseudomonas aeruginosa in Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives

  2020cited by this paper
• Influence of azithromycin and allograft rejection on the post-lung transplant microbiota.

  2019cited by this paper
• Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections

  2018cited by this paper
• Pseudomonas aeruginosa in Chronic Lung Infections: How to Adapt Within the Host?

  2018cited by this paper
• Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation

  2017cited by this paper
• Airway Microbiota Determines Innate Cell Inflammatory or Tissue Remodeling Profiles in Lung Transplantation.

  2016cited by this paper
• Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction

  2016cited by this paper
• Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

  2013cited by this paper
• Cutting Edge: Pseudomonas aeruginosa Abolishes Established Lung Transplant Tolerance by Stimulating B7 Expression on Neutrophils

  2012cited by this paper
• The Th17 pathway in cystic fibrosis lung disease.

  2011cited by this paper
• Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway

  2010cited by this paper
• Frequency of Pseudomonas aeruginosa colonizations/infections in lung transplant recipients.

  2009cited by this paper
• De novo or persistent pseudomonal airway colonization after lung transplantation: importance for bronchiolitis obliterans syndrome?

  2008cited by this paper
• Pseudomonas aeruginosa Colonization of the Allograft After Lung Transplantation and the Risk of Bronchiolitis Obliterans Syndrome

  2008cited by this paper
• Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation?

  2008cited by this paper
• Antimicrobial peptides in lung transplant recipients with bronchiolitis obliterans syndrome

  2008cited by this paper
• Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen

  2005cited by this paper
• A comparison of the antigen‐presenting capabilities of class II MHC‐expressing human lung epithelial and endothelial cells

  1997cited by this paper
• A study of bronchus-associated lymphoid tissue in a rat model of chronic pulmonary infection with Pseudomonas aeruginosa.

  1997cited by this paper
• Human ciliated bronchial epithelial cells: expression of the HLA-DR antigens and of the HLA-DR alpha gene, modulation of the HLA-DR antigens by gamma-interferon and antigen-presenting function in the mixed leukocyte reaction.

  1990cited by this paper

• No citing papers are available for this paper.